According to its partners' needs, CALYM offers to carry out the research and co-development of lymphoma biomarkers in this way:

**CALYM** (and possibly its industrial partners):
- carries out the biomarker discovery phase and establishes the proof of concept
- transfers the biomarker/the technology
- carries out the clinical validation phase

**CALYM's partner (in vitro diagnosis, biotechnology, pharmaceutical company)**
- products and qualifies analytically the assay (kit)
- obtains the CE marking authorization
- carries out the commercialization and distribution phase

---

**Drug Development**

- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Marketing Authorization Application

**Biomarker Development**

- Biomarker Discovery & Development
- Tech Transfer & Assay Faisability
- Test Development & Validation
- Regulatory Submission & Test Commercialization

---

**Your Needs & Collaboration Entry Options**

**You are looking for novel opportunities**
> CALYM offers biomarker identification & test development

**You need to validate your assay or platform in large specific cohorts**
> CALYM can give you access to its cohorts, collections and databases

---

**CALYM's Needs**

CALYM is looking for partner for IVD manufacturing & global commercialization for its proprietary biomarkers

---

**CONTACT US!**
partnering@calym.org - +33 4 72 66 93 33
www.calym.org
In order to improve diagnosis, guide therapy decisions and/or predict tumor responses, CALYM researchers develop new lymphoma biomarkers (tissue, blood, imaging) in collaboration with industry.

**CALYM EXPERTISE**

- Discovery of new lymphoma biomarkers (diagnosis, prognosis, pharmacodynamics, clinical response predictive, surrogate, safety…)
- Clinical validation in large cohorts and registration as part of a clinical trial
- Assay development for the clinical setting (e.g. from oriented genome-wide technologies to routine technologies such as RT-MLPA)

**CALYM RESOURCES & MEANS**

- Access to data
  - All types: genomic, transcriptomic, immunohistochemistry, imaging, clinical, etc.
- Sources
  - Pre-existing CALYM datasets
  - Profiles of samples from the CALYM clinically annotated biological collections
  - De novo sample collection as part of clinical trials
  - Data from CALYM pre-clinical models (cell lines, mice…)
- Analytical expertise (bioinformatics & biostatistics)
  - Screening, feature selection and model construction (gene signatures, IHC algorithm…)
  - from training set
  - Validation in independent dataset

**KEY FIGURES**

- **CEVI COLLECTION**: 700+ SAMPLES OF HUMAN VIABLE CELLS FROM LYMPHOMAS AND REACTIVE TISSUES
- **TENOMIC COLLECTION**: CLINICALLY ANNOTATED SAMPLES OF T-CELL LYMPHOMA FROM 900+ PATIENTS
- **CLINICALLY ANNOTATED PROPRIETARY DATABASE OF 23,000+ LYMPHOMA PATIENTS**
- **IMAGING PROPRIETARY DATABASE OF 18,000+ EXAMINATIONS**

**CONTACT US!**

partnering@calym.org - +33 4 72 66 93 33
www.calym.org